RhumbLine Advisers
BCAX

RhumbLine Advisers’s Bicara Therapeutics BCAX Stock Holding History

RhumbLine Advisers’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$810K Buy
40,747
+164
+0.4% +$2.82K ﹤0.01% 2309
2025
Q4 		$683K Sell
40,583
-5,036
-11% -$86K ﹤0.01% 2459
2025
Q3 		$720K Sell
45,619
-1,292
-3% -$14.5K ﹤0.01% 2447
2025
Q2 		$436K Buy
46,911
+23,893
+104% +$285K ﹤0.01% 2769
2025
Q1 		$300K Buy
23,018
+4,010
+21% +$53.3K ﹤0.01% 2891
2024
Q4 		$331K Buy
+19,008
New +$396K ﹤0.01% 2933

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

RhumbLine Advisers's BCAX Position: Q1 2026 in Review

RhumbLine Advisers increased its Bicara Therapeutics (BCAX) stake by 0.4% in Q1 2026, buying an estimated $2.82K and bringing the position to 40,747 shares worth $810K. The position accounts for ﹤0.01% of the portfolio, ranked #2309.

RhumbLine Advisers first reported a position in BCAX in Q4 2024 and has held it in 6 quarters since. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • RhumbLine Advisers held 40,747 shares of Bicara Therapeutics worth $810K as of Q1 2026.
  • RhumbLine Advisers bought 164 Bicara Therapeutics shares in Q1 2026, an estimated $2.82K.
  • Bicara Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #2309 holding.
  • RhumbLine Advisers first reported a position in Bicara Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.